Table 1. Baseline characteristics of patients in the two groups.
| Characteristics | Results | |
|---|---|---|
| ALPPS group (n=38) | TACE + PVE group (n=38) | |
| Age (yr) | 48.5 (27.0–68.0) | 51 (32.0–72.0) |
| Sex, male, n (%) | 34 (89.5%) | 32 (84.2%) |
| BMI | 23.7 (19.7–31.1) | 23.0 (20.6–28.6) |
| ASA operative risk, n (%) | ||
| I | 5 (13.2%) | 7 (18.4%) |
| II | 33 (86.8%) | 31 (81.6%) |
| III | 0 | 0 |
| ECOG score, n (%) | ||
| 0 | 30 (78.9%) | 28 (73.7%) |
| 1 | 8 (21.1%) | 10 (26.3%) |
| 2 | 0 | 0 |
| HBV-DNA >50 IU/mL, n (%) | 18 (47.4%) | 21 (55.3%) |
| HCV+, n (%) | 0 | 1 (2.6%) |
| TB (μmol/L) | 13.3 (6.7–28.0) | 13.2 (5.4–31.0) |
| ALB (g/L) | 41.5 (35.1–51.3) | 40.1 (33.6–48.7) |
| Portal hypertension+, n (%) | 14 (36.8%) | 12 (31.6%) |
| Gastroesophageal varices, n (%) | 2 (5.3%) | 2 (5.3%) |
| Platelet count (109/L) | 152 (70.0–369.0) | 162 (65.0–365.0) |
| Spleen diameter (mm) | 101 (77.0–140.0) | 103 (79.0–136.0) |
| AFP >20 μg/L, n (%) | 23 (60.5%) | 27 (71.1%) |
| Fibrotouch (kPa) | 8.4 (4–21.2) | 10.4 (5.1–20.3) |
| Single tumor, n (%) | 19 (50%) | 17 (44.7%) |
| Diameter of tumor (cm) | 8 (3.0–13.0) | 8 (4.0–13.0) |
| Multiple tumors, n (%) | 19 (50%) | 21 (55.3%) |
| Sum of diameters (cm) | 12 (7.0–17.0) | 11 (5.0–15.0) |
| Sum of tumor volume (mL) | 451 (18.0–2,493.0) | 397 (9.0–1,677.0) |
| FLR1/BW | 0.72% (0.39–0.79%) | 0.65% (0.39–0.79%) |
| Child-Pugh stage (%) | ||
| A | 100 | 100 |
| 0 | 0 | 0 |
| A | 50 | 44.7 |
| B | 50 | 55.3 |
| C | 0 | 0 |
| D | 0 | 0 |
The registration number of FDA is K173595. FibroTouch: FibroTouch is a non-invasive detection system for liver fibrosis and has been approved by FDA. BMI, body mass index; TB, total bilirubin; ALT, alanine aminotransferase; ALB, albumin; ASA, American Society of Anesthesiologists; ECOG, Eastern Cooperative Oncology Group; FLR/BW, future liver remnant volume/body weight; BCLC stage, Barcelona Clinic Liver Cancer classification.